Emergency Allocation to Reinforce DRC’s Outbreak Response
In response to an urgent request from the government of the Democratic Republic of the Congo (DRC), the International Coordinating Group (ICG) on Vaccine Provision has authorized the immediate delivery of 70,000 doses of the Ervebo vaccine from the global emergency stockpile. The intervention aims to control the ongoing Bundibugyo virus disease outbreak in the region.
Although Ervebo is officially licensed and recommended specifically for outbreaks caused by the Zaire ebolavirus strain, public health authorities are deploying the supply to bolster outbreak containment and gather crucial clinical data.
Distribution Plan and Clinical Evaluation
The released stockpile will be distributed under a two-pronged strategy designed to safeguard high-risk individuals and advance scientific understanding:
- 20,000 doses will be dedicated to a Phase 3 clinical trial aimed at assessing the efficacy and immune response of the Ervebo vaccine against the Bundibugyo virus in human populations.
- 50,000 doses are earmarked for the immunization of healthcare and frontline emergency workers, adhering strictly to guidance from the World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE).
Evaluating Vaccine Cross-Protection and Informed Consent
While definitive evidence on whether Ervebo protects humans against the Bundibugyo strain remains undetermined, preliminary laboratory and animal models indicate potential cross-protection. The forthcoming Phase 3 trial will supply vital empirical data to steer future policy decisions regarding vaccine deployment across differing viral strains.
Health authorities have emphasized that all vaccine recipients—both trial participants and frontline responders—must be comprehensively briefed on potential benefits, existing constraints, and associated risks to guarantee transparent informed consent.
Global Partnership and Community-Led Action
The ICG framework is coordinated jointly by the World Health Organization (WHO), Médecins Sans Frontières (MSF), UNICEF, and the International Federation of Red Cross and Red Crescent Societies (IFRC), with essential funding provided by Gavi, the Vaccine Alliance.
Both WHO and the Africa Centres for Disease Control and Prevention (Africa CDC) have commended the rapid allocation. Emphasizing a community-driven response, both institutions affirmed their commitment to partnering with the DRC government to halt viral transmission, safeguard vulnerable communities, and build lasting outbreak resilience across Africa.
Background on Emergency Vaccine Stockpiles
Formed in 1997 following severe meningitis epidemics in Africa, the ICG manages global emergency reserves to ensure equitable, rapid access to life-saving vaccines for diseases such as cholera, meningitis, yellow fever, and Ebola during health crises.
Since the official establishment of the dedicated Ebola vaccine reserve in January 2021, tens of thousands of Ervebo doses have been dispatched for active outbreak containment in the DRC, alongside more than 167,000 preventive doses administered to high-risk personnel across Uganda, Guinea-Bissau, Kenya, and Sierra Leone.
